Home › Sindromi mielodisplastiche › Massachusetts › Boston
Studi clinici su Sindromi mielodisplastiche a Boston, MA
19 studi su Sindromi mielodisplastiche cercano partecipanti presso sedi a Boston e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
In reclutamentoFase 2
- Tufts Medical Center, Boston
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
In reclutamentoFase 1
- Dana-Farber Cancer Institute, Boston
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
In reclutamentoFase 2
- Tufts Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
In reclutamentoFase 1/2
- Dana-Farber Cancer Institute, Boston
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
In reclutamentoFase 3
- Massachusetts General Hospital, Boston
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
In reclutamentoFase 1/2
- Dana-Farber Cancer Institute, Boston
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
In reclutamentoFase 1Volontari sani benvenuti
- Brigham and Women's Hospital, Boston
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
In reclutamentoFase 1
- Boston Children's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
In reclutamentoFase 1
- Dana-Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
In reclutamentoFase 1
- Dana Farber Cancer Institute, Boston
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
In reclutamentoStudio osservazionale
- Dana-Farber Cancer Institute, Boston
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
In reclutamentoFase 2/3
- Dana-Farber Cancer Institute, Boston
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
In reclutamentoFase 1/2
- Massachusetts General Hospital, Boston
Venetoclax Basket Trial for High Risk Hematologic Malignancies
In reclutamentoFase 1
- Dana-Farber Cancer Institute, Boston
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
In reclutamentoFase 2Volontari sani benvenuti
- DFCI/BWH Brigham and Women's Hospital, Boston
IS-free Treg HaploHCT
In reclutamentoFase 1
- Dana Farber Cancer Institute, Boston
HEME Home Transfusion Program
In reclutamento
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Study of REM-422 in Patients With AML or Higher Risk MDS
In reclutamentoFase 1
- Massachusetts General Hospital, Boston
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
In reclutamentoFase 1
- Dana-Farber Cancer Institute, Boston
Studi su Sindromi mielodisplastiche in altre città
- Houston, TX43 studi
- Baldwin Park, CA26 studi
- New York City, NY21 studi
- Seattle, WA21 studi
- Washington, DC20 studi
- Tampa, FL19 studi
- Miami, FL17 studi
- Columbus, OH14 studi
- Durham, NC14 studi
- Chicago, IL13 studi
- Atlanta, GA13 studi
- St. Louis, MO13 studi
Altri studi a Boston
- Cancro al seno111 studi
- Cancro del polmone non a piccole cellule90 studi
- Cancro (tutti i tipi)86 studi
- Cancro colorettale63 studi
- Cancro metastatico63 studi
- Cancro ai polmoni62 studi
- Cancro ovarico61 studi
- Cancro alla prostata59 studi
- Depressione52 studi
- Cancro dell'endometrio50 studi
- Insufficienza cardiaca44 studi
- Leucemia mieloide acuta44 studi
Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.